(Z)-4-bromostyryl-4-fluorobenzylsulfone | 298197-19-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-4-bromostyryl-4-fluorobenzylsulfone
• 英文别名: 1-[[(Z)-2-(4-bromophenyl)ethenyl]sulfonylmethyl]-4-fluorobenzene
• CAS: 298197-19-0
• 化学式: C₁₅H₁₂BrFO₂S
• 分子量: 355.227
• InChiKey: URBLDUHDENNTET-KTKRTIGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (4-溴苯基)乙炔 、 (Z)-4-bromostyryl 4-fluorobenzylsulfide 、 4-氟苄基硫醇 以78%的产率得到(Z)-4-bromostyryl-4-fluorobenzylsulfone
  参考文献：
  名称：

  Z-styryl sulfone anticancer agents

  摘要：

  式I中的(Z)-苯乙烯基苯基磺酮可用作抗癌剂：其中，R1选自氢、氯和硝基组成的群体；R2选自氢、较低的烷基、较低的烷氧基、氯、溴和氟组成的群体；R3和R4独立地选自氢、较低的烷基、硝基、氯、溴和氟组成的群体；前提是R1或R2中至少有一个是氢。相应的(Z)-苯乙烯基苯基硫醚可用作生物活性的(Z)-苯乙烯基苯基磺酮的中间体。

  公开号：

  US06201154B1

文献信息

• Z-styryl sulfone anticancer agents
  申请人：Temple University - Of the Commonwealth System of Higher Education

  公开号：US06576675B1

  公开（公告）日：2003-06-10

  (Z)-styryl benzylsulfones of formula I are useful as anticancer agents: wherein R1 is selected from the group consisting of hydrogen, chloro and nitro; R2 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, chloro, bromo, iodo and fluoro; and R3 and R4 are independently selected from the group consisting of hydrogen, lower alkyl, nitro, chloro, bromo, iodo and fluoro; provided that at least one of R1 or R2 is hydrogen. The corresponding (Z)-styryl benzylsulfides are useful as intermediates in the preparation of the biologically active (Z)-styryl benzyl sulfones.

  式I的(Z)-苯乙烯基苯基磺酮是作为抗癌剂有用的化合物，其中：R1选自氢、氯和硝基的群体；R2选自氢、较低的烷基、较低的烷氧基、氯、溴、碘和氟的群体；R3和R4独立地选自氢、较低的烷基、硝基、氯、溴、碘和氟的群体；但要求至少R1和R2中的一个是氢。相应的(Z)-苯乙烯基苯基硫醚是制备具有生物活性的(Z)-苯乙烯基苯基磺酮的中间体。
• Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
  申请人：——

  公开号：US20040214903A1

  公开（公告）日：2004-10-28

  Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.

  预处理使用α，β不饱和芳基磺酮可以保护正常细胞免受两类抗癌化疗药物的细胞毒副作用。在使用有丝分裂期细胞周期抑制剂或拓扑异构酶抑制剂的抗癌化疗前向患者给予细胞保护性磺酮化合物，可以减少或消除抗癌药物对正常细胞的细胞毒副作用。α，β不饱和芳基磺酮的细胞保护作用使临床医生可以安全地增加抗癌化疗药物的剂量。
• Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones
  申请人：——

  公开号：US20030060505A1

  公开（公告）日：2003-03-27

  Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the toxic side effects of ionizing radiation. Administration of a radioprotective &agr;,&bgr; unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increase the dosage of anticancer radiation. In some instances, amelioration of toxicity following inadvertent radiation exposure may be mitigated with administration of &agr;,&bgr; unsaturated arylsulfone.

  预处理使用α，β不饱和芳基磺酮可以保护正常细胞免受电离辐射的毒副作用。在抗癌放疗之前向患者给予放射性保护α，β不饱和芳基磺酮化合物可以减少辐射对正常细胞的细胞毒性副作用。α，β不饱和芳基磺酮的辐射保护效果可以让临床医生安全地增加抗癌放射剂量。在某些情况下，无意中接触辐射后毒性的缓解可以通过给予α，β不饱和芳基磺酮来缓解。
• Formulations of radioprotective alpha, beta unsaturated aryl sulfones
  申请人：Onconova Therapeutics, Inc.

  公开号：EP2769719A1

  公开（公告）日：2014-08-27

  Solution and suspension formulations are provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject which comprises an effective amount of at least one radioprotective α, β unsaturated aryl sulfone wherein the composition has a pH within the range of about 8 to about 9.

  本发明提供了溶液和悬浮液制剂，用于在电离辐射照射前或照射后给药，以减少辐射对受试者的毒性影响，该制剂包含有效量的至少一种辐射保护性 α、β 不饱和芳基砜，其中组合物的 pH 值在约 8 到约 9 的范围内。
• EP1180024A4
  申请人：——

  公开号：EP1180024A4

  公开（公告）日：2002-06-19